Key Takeaways
- • CereVasc closed an $85 million Series C financing round led by Piper Sandler Merchant Banking, with participation from Johnson & Johnson Innovation (JJDC) and Medtronic, alongside existing backers Bain Capital Life Sciences and Perceptive Xontogeny Venture Funds.
- • The Boston-based clinical-stage medical device company is developing the eShunt System, a minimally invasive, endovascularly implantable cerebrospinal fluid shunt designed to treat communicating hydrocephalus without traditional surgical intervention.
- • CereVasc's technology employs a patented percutaneous transvenous-transdural approach to access the central nervous system, representing a novel therapeutic pathway for a patient population currently limited to more invasive treatment options.
- • Strategic participation from Johnson & Johnson and Medtronic—both major medical device and healthcare conglomerates—signals significant commercial validation and potential pathway acceleration toward clinical adoption and regulatory approval.
Summary
CereVasc announced the successful completion of an $85 million Series C financing, marking a substantial capital injection for the clinical-stage medical device company. Piper Sandler Merchant Banking led the round, with strategic participation from two marquee healthcare industry players: Johnson & Johnson Innovation (JJDC), the corporate venture capital arm of J&J, and Medtronic. Existing investors Bain Capital Life Sciences and Perceptive Xontogeny Venture Funds also participated in the financing.
The company, based in Boston, is focused on developing minimally invasive treatments for neurological diseases, with its lead product—the eShunt System—positioned to address a significant unmet clinical need. Communicating hydrocephalus, a condition characterized by excess cerebrospinal fluid in the brain, has historically required invasive surgical procedures. CereVasc's eShunt System employs a proprietary percutaneous transvenous-transdural approach, allowing physicians to implant an endovascularly placed cerebrospinal fluid shunt without traditional open surgery. The technology is patent-protected and designed to expand treatment accessibility while potentially reducing patient morbidity associated with conventional surgical intervention.
The participation of both Johnson & Johnson and Medtronic carries strategic weight beyond capital deployment. Both companies are established leaders in medical devices and neurological treatments, suggesting they view CereVasc's technology as clinically promising and commercially viable. Their involvement may facilitate regulatory pathway discussions, clinical trial design, and eventual distribution and commercialization channels—advantages that extend beyond the $85 million raise itself. For institutional investors and hedge funds tracking medical device innovation, this round underscores continued investor appetite for novel approaches to chronic neurological conditions that affect millions globally.
The company, based in Boston, is focused on developing minimally invasive treatments for neurological diseases, with its lead product—the eShunt System—positioned to address a significant unmet clinical need. Communicating hydrocephalus, a condition characterized by excess cerebrospinal fluid in the brain, has historically required invasive surgical procedures. CereVasc's eShunt System employs a proprietary percutaneous transvenous-transdural approach, allowing physicians to implant an endovascularly placed cerebrospinal fluid shunt without traditional open surgery. The technology is patent-protected and designed to expand treatment accessibility while potentially reducing patient morbidity associated with conventional surgical intervention.
The participation of both Johnson & Johnson and Medtronic carries strategic weight beyond capital deployment. Both companies are established leaders in medical devices and neurological treatments, suggesting they view CereVasc's technology as clinically promising and commercially viable. Their involvement may facilitate regulatory pathway discussions, clinical trial design, and eventual distribution and commercialization channels—advantages that extend beyond the $85 million raise itself. For institutional investors and hedge funds tracking medical device innovation, this round underscores continued investor appetite for novel approaches to chronic neurological conditions that affect millions globally.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.